Corifollitropin alfa FDA Approval Status
Corifollitropin alfa is a sustained follicular stimulant in development for use in a fertility treatment regimen.In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for corifollitropin alfa. Merck is evaluating the information provided in the CRL. Corifollitropin alfa is marketed as Elonva in more than 75 countries.
Development Timeline for corifollitropin alfa
|Jul 29, 2014||Merck Receives Complete Response Letter from the U.S. FDA for New Drug Application for Corifollitropin Alfa|
|Sep 9, 2013||Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.